Browsing by author "Huang, Paul"
Now showing items 41-60 of 72
-
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas.
Merry, E; Thway, K; Jones, RL; Huang, PH (NATURE PORTFOLIO, 2021-03-05)Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80 different histological subtypes. Treatment options remain limited in advanced STS with high rates of recurrence following resection of localised ... -
Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer.
Jenks, AD; Vyse, S; Wong, JP; Kostaras, E; Keller, D; et al. (CELL PRESS, 2018-06-05)Primary cilia are microtubule-based organelles that detect mechanical and chemical stimuli. Although cilia house a number of oncogenic molecules (including Smoothened, KRAS, EGFR, and PDGFR), their precise role in cancer ... -
Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas.
Chadha, M; Huang, PH (SPRINGER, 2022-02-16)Advances in proteomic and metabolomic technologies have accelerated our understanding of multiple aspects of cancer biology across distinct tumour types. Here we review the current state-of-the-art in the use of proteomics ... -
Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis.
Krasny, L; Wilding, CP; Perkins, E; Arthur, A; Guljar, N; et al. (MDPI, 2022-06-13)Intravenous leiomyomatosis (IVLM) is a rare benign smooth muscle tumour that is characterised by intravenous growth in the uterine and pelvic veins. Previous DNA copy number and transcriptomic studies have shown that IVLM ... -
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
Milighetti, M; Krasny, L; Lee, ATJ; Morani, G; Szecsei, C; et al. (ELSEVIER, 2021-06-15)Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise ... -
Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
Vyse, S; McCarthy, F; Broncel, M; Paul, A; Wong, JP; et al. (ELSEVIER SCIENCE BV, 2018-01-06)UNLABELLED: Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapies ... -
Radiomic Features From Diffusion-Weighted MRI of Retroperitoneal Soft-Tissue Sarcomas Are Repeatable and Exhibit Change After Radiotherapy.
Thrussell, I; Winfield, JM; Orton, MR; Miah, AB; Zaidi, SH; et al. (FRONTIERS MEDIA SA, 2022-07-18)BACKGROUND: Size-based assessments are inaccurate indicators of tumor response in soft-tissue sarcoma (STS), motivating the requirement for new response imaging biomarkers for this rare and heterogeneous disease. In this ... -
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Harrison, PT; Vyse, S; Huang, PH (ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2020-04-01)Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 deletions and the L858R point mutation) ... -
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
Goggin, C; Stansfeld, A; Mahalingam, P; Thway, K; Smith, MJ; et al. (FUTURE MEDICINE LTD, 2022-07-26)Over the past 20 years, the management of gastrointestinal stromal tumors has acted as an important model in the advancement of molecularly targeted therapies for solid tumors. The success of imatinib has established it ... -
Sirolimus for patients with progressive epithelioid hemangioendothelioma.
Smrke, AM; Huang, PH; Jones, RL (WILEY, 2020-10-27)Epithelioid hemangioendothelioma is an ultrarare soft tissue sarcoma with limited literature to guide treatment. The results from a robust retrospective cohort study support the use of sirolimus for patients who have ... -
Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma.
Smrke, A; Thway, K; H Huang, P; Jones, RL; Hayes, AJ (FUTURE MEDICINE LTD, 2021-09-01)Solitary fibrous tumor (SFT) is a rare soft tissue sarcoma subtype which mainly affects adults in the fifth and sixth decades of life. Originally part of a spectrum of tumors called hemangiopericytomas, classification has ... -
Spatial localisation of Discoidin Domain Receptor 2 (DDR2) signalling is dependent on its collagen binding and kinase activity.
Luczynski, MT; Harrison, PT; Lima, N; Krasny, L; Paul, A; et al. (ACADEMIC PRESS INC ELSEVIER SCIENCE, 2018-06-18)Discoidin Domain Receptor 2 (DDR2) is a collagen-binding receptor tyrosine kinase that initiates delayed and sustained tyrosine phosphorylation signalling. To understand the molecular basis of this unique phosphorylation ... -
SWATH mass spectrometry as a tool for quantitative profiling of the matrisome.
Krasny, L; Bland, P; Kogata, N; Wai, P; Howard, BA; et al. (ELSEVIER, 2018-03-01)Proteomic analysis of extracellular matrix (ECM) and ECM-associated proteins, collectively known as the matrisome, is a challenging task due to the inherent complexity and insolubility of these proteins. Here we present ... -
Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.
Todd, JR; Ryall, KA; Vyse, S; Wong, JP; Natrajan, RC; et al. (IMPACT JOURNALS LLC, 2016-08-17)Tumour cell-extracellular matrix (ECM) interactions are fundamental for discrete steps in breast cancer progression. In particular, cancer cell adhesion to ECM proteins present in the microenvironment is critical for ... -
Systemic therapy is effective in the management of leiomyomatosis
Smrke, A; Ostler, A; Yusuf, S; Miah, AB; Thway, K; et al. (MRE PRESS, 2022-06-14) -
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network.
Smrke, A; Frezza, AM; Giani, C; Somaiah, N; Brahmi, M; et al. (ELSEVIER, 2022-06-01)BACKGROUND: Clear cell sarcoma (CCS) is a translocated aggressive malignancy with a high incidence of metastases and poor prognosis. There are few studies describing the activity of systemic therapy in CCS. We report a ... -
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini, L; Jenks, AD; Vyse, S; Wilding, CP; Arthur, A; et al. (DOVE MEDICAL PRESS LTD, 2021-03-08)Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted ... -
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.
Vyse, S; Huang, PH (SPRINGERNATURE, 2019-03-08)Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic drivers in non-small cell lung cancer (NSCLC). ... -
Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.
Pacini, L; Jenks, AD; Lima, NC; Huang, PH (MDPI, 2021-05-10)Lung cancer is the most common cause of cancer-related deaths globally. Genetic alterations, such as amplifications, mutations and translocations in the fibroblast growth factor receptor (FGFR) family have been found in ... -
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima, NC; Atkinson, E; Bunney, TD; Katan, M; Huang, PH (MDPI, 2020-05-01)Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. ...